In Lewy body diseases, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), alpha-synuclein accumulates intraneuronally in the central and peripheral nervous systems [1, 3, 8]. Recent studies [3, 6] have suggested that spread of alpha-synuclein positive Lewy-related pathology (LRP) follows two distinct patterns—caudo-rostral progression and an amygdala-based progression, the latter usually seen together with Alzheimer’s disease (AD) pathology [6].

The olfactory system is affected in almost all PD and DLB cases. However, distribution and possible spreading routes of olfactory pathology may differ between PD and DLB [2]. In this context, a hospital-based neuropathological study indicated that LRP in olfactory bulb (OB) can be identified in two anatomically different areas: anterior olfactory nucleus (referred as AON) and periphery of the OB (referred to as peripheral) [7]. AON pathology was strongly associated with a high burden of LRP in amygdala [7].

We have previously investigated the brain and spinal cord LRP in a population-based sample [6]. Here, we analyzed LRP in the olfactory regions (OB and olfactory peduncle, OP) to complement our previous study and to test how this LRP pathology correlates with LRP patterns in the brain.

Materials and methods have been described in detail previously [6] (see also online resource). Briefly, OB/OP samples of Finns aged 85 or over (Vantaa 85+ cohort) were collected, fixed in formalin and embedded in paraffin. Sections of the samples were stained using alpha-synuclein antibody 5G4. Two assessors blinded to clinical, genetic and neuropathological information screened AON and peripheral regions and graded LRP semi-quantitatively based on the grading system used by Sengoku et al. [7] and DLB Consortium guidelines [4]. The highest two grades (3–4) were merged to retain statistical power.

The Vantaa 85 + study’s neuropathological cohort included 291 cases with OB/OP samples. 119 (41%) were scored positive for alpha-synuclein immunohistochemical staining. Of our positive OB/OP cases, 110 (92%) cases were positive in both AON and peripheral and 9 (8%) only in peripheral. No cases were AON-only positive. Based on staining intensity, we classified 79 cases (66%) as AON predominant and 21 cases (18%) as peripherally predominant. The predominance was unclear in 19 (16%) cases. In general, there was more staining in AON than periphery of olfactory regions. Table 1 reveals the alpha-synuclein positivity in OB/OP samples grouped according to DLB Consortium classifications [5] and LRP progression-based categorisation [6]. Figure 1 displays how OB/OP predominance relates to caudo-rostral and amygdala-based LRP progression type. Further results are shown in the online resource.

When considering the DLB Consortium classification, our results suggest that strong AON positivity is associated
with strong DLB pathology, particularly neocortical DLB (Table 1, online resource Fig. 1 and Table 1, p < 0.001). All amygdala-predominant cases (DLB Consortium classification) were OB/OP positive. Brainstem-predominant DLB cases had no or mild positivity for OB/OP pathology (Table 1, online resource Table 1). All non-classifiable cases (DLB Consortium classification with minimal medulla pathology) were negative for OB/OP pathology. Generally, cases with mild or no LRP pathology or pathology only in the brainstem tended to be negative for OB/OP pathology, whereas cases with strong LRP throughout the brain also had strong AON and peripheral OB/OP pathology (mostly with AON predominance, Fig. 1, online resource).

When considering the dichotomous (caudo-rostral or amygdala-based) progression-based classification [6], the predominance of OB/OP alpha-synuclein patterns were pronounced (Fig. 1, p < 0.001). Amygdala-based cases tended to have AON predominance compared to caudo-rostral cases. None of the amygdala-based cases were negative for OB/OP pathology, whereas 23% of caudo-rostral cases were negative (Fig. 1, Table 1). In general, caudo-rostral cases showed milder OB/OP pathology (both peripheral and AON) (Table 1). K-means clustering of our OB/OP data and with other measured brain regions showed similar grouping (Fig. 2, online resource), in concordance with our previous results [6].

Interestingly, there were 15 cases (13%) positive for LRP only in OB/OP (not in brain or brainstem). These had modest AON and peripheral LRP pathology (see Table 2, online resource). On closer inspection, these cases had variable AD-type pathology, and in most cases (13, except two indeterminate) had peripherally predominant OB/OP LRP. A possible explanation could be early stage alpha-synuclein accumulation in these cases. This would be consistent with the previous study by Sengoku et al. suggesting that the OB/OP pathology begins in the periphery, and later proceeds to

| Table 1 Characteristics of the Vantaa 85+ Study and Olfactory bulb/peduncle Lewy-related (LRP) pathology categorised by DLB Consortium classification [5] and LRP progression-based classification [6] |

| No LRP [6] | LRP detected |
|------------|--------------|
| DLB consortium classification [5] n = 119 | LRP progression-based [6] n = 118 |
| Non-classifiable | Brainstem | Amygdala predominant | Limbic | Diffuse Neocortical | Caudo-rostral | Amygdala-based |
| n = 172 | n = 117 | n = 10 | n = 40 | n = 41 | n = 80 | n = 38 |
| Women % | 85 | 84 | 80 | 74 | 76 | 76 |
| Mean age at death (years) | 92.3 | 93.0 | 92.3 | 92.2 | 92.6 | 92.3 |
| Periphery LRP (n, %) | | | | | | |
| None | 157 (91.3) | 11 (100) | 4 (23.5) | 0 (0) | 0 (0) | 0 (0) | 15 (18.8) | 0 (0) |
| Sparse positivity | 13 (7.6) | 0 (0) | 9 (52.9) | 7 (70.0) | 34 (85.0) | 29 (70.7) | 51 (63.7) | 27 (71.1) |
| Scattered positivity | 2 (1.2) | 0 (0) | 4 (23.5) | 3 (30.0) | 6 (15.0) | 12 (29.3) | 14 (17.5) | 11 (28.9) |
| Dense positivity | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| AON LRP (n, %) | | | | | | |
| None | 163 (94.8) | 11 (100) | 5 (29.4) | 0 (0) | 2 (5.0) | 0 (0) | 18 (22.5) | 0 (0) |
| Sparse positivity | 9 (5.2) | 0 (0) | 9 (52.9) | 3 (30.0) | 9 (22.5) | 0 (0) | 17 (21.3) | 4 (10.5) |
| Scattered positivity | 0 (0) | 0 (0) | 3 (17.6) | 4 (40.0) | 12 (30.0) | 3 (7.3) | 13 (16.3) | 9 (23.7) |
| Dense positivity | 0 (0) | 0 (0) | 0 (0) | 3 (30.0) | 17 (42.5) | 38 (92.7) | 32 (40.0) | 25 (65.8) |
| OB/OP LRP predominance (n, %) | | | | | | |
| Peripheral | 13 (86.7) | 0 (0) | 5 (38.5) | 1 (10.0) | 2 (5.0) | 0 (0) | 6 (9.2) | 2 (5.3) |
| AON | 0 (0) | 0 (0) | 2 (15.4) | 7 (70.0) | 29 (72.5) | 41 (100) | 44 (67.7) | 34 (89.5) |
| Unclassifiable | 2 (13.3) | 0 (0) | 6 (46.2) | 2 (20.0) | 9 (22.5) | 0 (0) | 15 (23.1) | 2 (5.3) |

aScattered = 1–3 LB at 100× magnification; dense ≥ 4 LB at 100× magnification, according to [7]. LN were measured visually. Dense groups were combined to retain statistical significance. AON anterior olfactory nucleus, LRP Lewy-related pathology, OB/OP Olfactory bulb/Olfactory peduncle. Case numbers of DLB Consortium classification and LRP progression-based differ due to one case being omitted from analyses in [6] for having extremely high alpha-synuclein pathology. bThe unclassifiable category doesn’t include samples that had no peripheral and no AON LRP.
the anterior olfactory nucleus [7]. This interpretation is also consistent with the finding that there were no cases in our study cohort that were positive only in the anterior olfactory nucleus.

Substantia nigra neuron loss was significantly associated with OB/OP staining (see Fig. 3, online resource, \( p < 0.001 \)). AD pathology according to Braak staging was significantly associated with OB/OP staining patterns (see Table 1, online resource, \( p = 0.002 \) comparing none versus all positive OB/OP staining), but not with CERAD scores. OB/OP staining predominance showed a trend towards association with moderate or frequent CERAD score but was not significant (82% AON predominance versus 62% peripheral, \( p = 0.07 \)). Consistent with the AD pathology results, analysis by OB/OP predominance showed \( APOE \) \( e4 \) was found in 49% of the AON predominant cases versus 26% of peripheral cases but was not significant after age and sex correction (\( p = 0.10 \)). The number of cases with dementia when comparing OB/OP staining predominance were 66 (83.5%) subjects with the AON predominance versus 12 (57%) cases in the peripheral predominance group (\( p = 0.006 \)).

Whilst these results are from a post-mortem study that has a relatively small number of cases, it is the first report of OB/OP alpha-synuclein pathology in an unselected, population-based cohort. It should be noted, however, that this 85+ population may consist of superaged Finnish individuals that may not be directly comparable to the general population or to genetically more heterogeneous populations outside of Finland. In addition, the cohort has a large proportion of females, but was corrected for in statistical analyses.

In conclusion, our population based results showed that 41% of all cases had OB/OP alpha-synuclein pathology, and it was strongly associated with alpha-synuclein pathology elsewhere in the brain. Our results provide further support to the hypothesis of at least two divergent spreading routes of alpha-synuclein pathology.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00401-021-02364-6.

Acknowledgements This study was supported by the Academy of Finland (294817), Helsinki University Central Hospital, State Funding for University-level Health Research (TYH2020231, TYH2018217), Medicinska Understödföreningen Liv och Hälsa rf, and the Finnish Cultural Foundation. We thank the Vantaa 85+ Study establishers (Raimo Sulkava and Leena Niinistö), the researchers and collaborators over the years, as well as the participants, their families and caregivers. Kristiina Nokelainen is acknowledged for excellent technical assistance.
Funding Open access funding provided by University of Helsinki including Helsinki University Central Hospital.

Declarations

Conflict of interests Pentti J. Tienari holds a patent on C9orf72 in diagnostics and treatment of ALS/FTD and has made paid consultations to Roche, Biogen, Merck, Teva, Sanofi-Genzyme and Novartis. Other authors declare no conflicts of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants or their relatives.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G et al (2021) Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol 141(2):159–172. https://doi.org/10.1007/s00401-020-02255-2

2. Cersosimo MG (2018) Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies. Cell Tissue Res 373(1):233–243. https://doi.org/10.1007/s00441-017-2733-6

3. Horsager J, Andersen KB, Knudsen K, Skjærbæk C, Fedorova TD, Okkels N et al (2020) Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain 143(10):3077–3088. https://doi.org/10.1093/brain/awaa238

4. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872. https://doi.org/10.1212/01.wnl.0000187889.17253.b1

5. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1):88–100. https://doi.org/10.1212/WNL.000000000004058

6. Raunio A, Kaivola K, Tuimala J, Kero M, Oinas M, Polvikoski T et al (2019) Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. Acta Neuropathol 138(5):771–782. https://doi.org/10.1007/s00401-019-02071-3

7. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K et al (2008) Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67(11):1072–1083. https://doi.org/10.1097/NEN.0b013e31818b4126

8. Tanei ZI, Saito Y, Ito S, Matsubara T, Motoda A, Yamazaki M et al (2020) Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol 141(1):25–37. https://doi.org/10.1007/s00401-020-02233-8

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.